

Treatment eligibility



Treatment
eligibility
criteria

Treatment
candidate

Contraindicated
patient



Treatment eligibility

MRI-based contraindications


- A history of macrohemorrhages
- More than 4 microhemorrhages
- Evidence of superficial siderosis
- Evidence of brain vasogenic edema
- Significant white matter hyperintensities
- Multiple lacunar strokes
- Cerebral strokes involving a major vascular territory
- Central nervous system infection
- Evidence of cerebral contusion, encephalomalacia, brain aneurysms or other vascular malformations
- Brain tumors other than meningioma
- Arachnoid cysts
- Evidence of underlying cerebral amyloid angiopathy-related inflammation
- Evidence of Amyloid-Beta-related angiitis

Treatment eligibility


baba vision

Home Patients Reports Patient Astrid Holm Female / Age: 68 Timeline Baseline 2026-01-01 Assessments MRI T1 January 1, 2026 T2 FLAIR January 1, 2026 T2* January 1, 2026 SWI January 1, 2026 Genetic Markers APOE January 2, 2026 c3 TREM2 January 2, 2026 R47H Biological Tests pTau217 January 2, 2026 90th Ab42/40 January 2, 2026 12th NFL January 2, 2026 86th MRI contraindications 0 Macrohemorrhages 2 Microhemorrhages Absent Vasogenic edema 1 Lacunar strokes Moderate White matter hyperintensity load Treatment eligibility Legembi Eligible Kisunla Not eligible Disease status Differential Diagnosis 93% Alzheimer's disease Disease stage Stage 1/4 Mild cognitive impairment Predicted progression rate 85th Risk percentile

Explainable artificial intelligence



The future of Alzheimer's treatment



Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., Leisgang-Osse, A. M., & Cheng, F. (2025). Alzheimer's disease drug development pipeline: 2025. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 11(2), e70098.

The future of Alzheimer's treatment

baba vision

Home Patients Reports Patient Astrid Holm Female / Age: 68 Timeline Baseline 2030-07-04

Findings

Modality June 17, 2030 T1

Cognitive Scores MMSE June 10, 2030 28

Digital biomarkers Speech June 17, 2030 Value

Genetic Markers APOE4 May 12, 2030 Negative

Marker May 12, 2030 Value

Biological Tests pTau217 May 12, 2030 90th Percentile

Aβ42/40 May 12, 2030 12th

NFL May 12, 2030 86th

Treatment evaluation
AI-predicted treatment outcomes over 3 years.

Kisunila
≈ 5 months Delay in cognitive decline
10% Severe side-effect risk

Leqembi
≈ 7 months Delay in cognitive decline
7% Severe side-effect risk

Treatment X
≈ 12 months Delay in cognitive decline
55% Moderate side-effect risk

Treatment Y
Not eligible Patient does not meet early-stage criteria

No treatment
0 months Delay in cognitive decline
30% Risk of dementia progression

Thank you for your attention!
esten@baba-vision.com

baba vision

